Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

Biotechnologisch onderzoek

San Carlos, California 24.001 volgers

Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.

Over ons

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

Website
http://www.iovance.com/
Branche
Biotechnologisch onderzoek
Bedrijfsgrootte
501 - 1.000 medewerkers
Hoofdkantoor
San Carlos, California
Type
Naamloze vennootschap
Opgericht
2007
Specialismen
Immuno Oncology, Autologous Cell Therapy, Tumor Infiltrating Lymphocytes (TIL), Novel Cancer Immunotherapies en cell therapy

Locaties

Medewerkers van Iovance Biotherapeutics, Inc.

Updates

Vergelijkbare pagina’s

Door vacatures bladeren

Financiering

Iovance Biotherapeutics, Inc. 8 rondes in totaal

Laatste ronde

Vermogen na beursgang

US$ 211.000.000,00

Bekijk meer informatie over Crunchbase